MA51908A - Indazole-3-carboxamides substitués par hétéroaryle en position 5, préparation et utilisation associées - Google Patents

Indazole-3-carboxamides substitués par hétéroaryle en position 5, préparation et utilisation associées

Info

Publication number
MA51908A
MA51908A MA051908A MA51908A MA51908A MA 51908 A MA51908 A MA 51908A MA 051908 A MA051908 A MA 051908A MA 51908 A MA51908 A MA 51908A MA 51908 A MA51908 A MA 51908A
Authority
MA
Morocco
Prior art keywords
heteraryl
indazole
associated preparation
carboxamides substituted
carboxamides
Prior art date
Application number
MA051908A
Other languages
English (en)
Inventor
Venkataiah Bollu
Jianguo Cao
Chandramouli Chiruta
Brian Walter Eastman
Brian Joseph Hofilena
Sunil Kumar Kc
Chi Ching Mak
Gopi Kumar Mittapalli
Original Assignee
Samumed Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed Llc filed Critical Samumed Llc
Publication of MA51908A publication Critical patent/MA51908A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051908A 2018-02-23 2019-02-22 Indazole-3-carboxamides substitués par hétéroaryle en position 5, préparation et utilisation associées MA51908A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862634656P 2018-02-23 2018-02-23

Publications (1)

Publication Number Publication Date
MA51908A true MA51908A (fr) 2021-06-02

Family

ID=65812386

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051908A MA51908A (fr) 2018-02-23 2019-02-22 Indazole-3-carboxamides substitués par hétéroaryle en position 5, préparation et utilisation associées

Country Status (18)

Country Link
US (2) US10934297B2 (fr)
EP (1) EP3755696B1 (fr)
JP (1) JP7369132B2 (fr)
KR (1) KR102861944B1 (fr)
CN (1) CN112020501A (fr)
AU (1) AU2019224075A1 (fr)
BR (1) BR112020017087A2 (fr)
CA (1) CA3091913A1 (fr)
CL (1) CL2020002177A1 (fr)
EA (1) EA202092002A1 (fr)
ES (1) ES2945558T3 (fr)
IL (1) IL276814A (fr)
MA (1) MA51908A (fr)
MX (1) MX2020008852A (fr)
PE (1) PE20211447A1 (fr)
PH (1) PH12020551300A1 (fr)
SG (1) SG11202008029UA (fr)
WO (1) WO2019165192A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA51908A (fr) 2018-02-23 2021-06-02 Samumed Llc Indazole-3-carboxamides substitués par hétéroaryle en position 5, préparation et utilisation associées
MA52557A (fr) * 2018-05-07 2021-03-17 Acraf Composés de 1h-indazole-3-carboxamide utilisés en tant qu'inhibiteurs de la glycogène synthase kinase 3 bêta
WO2020059841A1 (fr) * 2018-09-21 2020-03-26 国立大学法人 長崎大学 Agent thérapeutique pour maladies à prions
KR102650856B1 (ko) * 2019-12-16 2024-03-25 한국화학연구원 신규한 인다졸 유도체 및 이의 용도
WO2021120890A1 (fr) * 2019-12-20 2021-06-24 Novartis Ag Dérivés pyrazolyle utiles en tant qu'agents anticancéreux
WO2024259121A1 (fr) * 2023-06-14 2024-12-19 Prothena Biosciences Limited Composés hétéroaromatiques bicycliques pour le traitement de troubles neurologiques

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
FR2867778B1 (fr) * 2004-03-16 2006-06-09 Sanofi Synthelabo Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
UA93348C2 (ru) * 2004-03-25 2011-02-10 Меморі Фармас'Ютікалз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
CA2560741C (fr) * 2004-03-25 2013-08-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
WO2011050245A1 (fr) * 2009-10-23 2011-04-28 Yangbo Feng Hétéroaryles bicycliques formant inhibiteurs de la kinase
WO2013024011A1 (fr) * 2011-08-12 2013-02-21 F. Hoffmann-La Roche Ag Composés d'indazole, compositions et procédés d'utilisation
EP3473099A1 (fr) 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation par wnt/b-caténine
WO2013124158A1 (fr) * 2012-02-21 2013-08-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Composés 1h-indazole-3-carboxamide en tant qu'inhibiteurs de la glycogène synthase kinase 3 bêta
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EP3119393A4 (fr) * 2014-03-20 2018-02-28 Samumed, LLC Indazole-3-carboxamides 5-substitués, et préparation et utilisation de ceux-ci
WO2016040182A1 (fr) * 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine et ses utilisations thérapeutiques
NZ742200A (en) 2015-11-06 2023-01-27 Samumed Llc Treatment of osteoarthritis
SI3464285T1 (sl) 2016-06-01 2023-02-28 Biosplice Therapeutics, Inc. Postopek za pripravo N-(5-(3-(7-(3-fluorofenil)-3H-imidazo(4,5-C)piridin-2-il)-1H-indazol-5- il)piridin-3-il)-3-metilbutanamida
EP3528808B1 (fr) 2016-10-21 2021-10-06 BioSplice Therapeutics, Inc. Procédés d'utilisation d'indazole-3-carboxamides et leur utilisation en tant qu'inhibiteurs de la voie de signalisation wnt/ -caténine
MA51908A (fr) 2018-02-23 2021-06-02 Samumed Llc Indazole-3-carboxamides substitués par hétéroaryle en position 5, préparation et utilisation associées

Also Published As

Publication number Publication date
ES2945558T3 (es) 2023-07-04
CA3091913A1 (fr) 2019-08-29
US10934297B2 (en) 2021-03-02
JP2021516674A (ja) 2021-07-08
KR20200126393A (ko) 2020-11-06
WO2019165192A1 (fr) 2019-08-29
EP3755696B1 (fr) 2023-04-05
US20190263821A1 (en) 2019-08-29
BR112020017087A2 (pt) 2020-12-22
SG11202008029UA (en) 2020-09-29
PH12020551300A1 (en) 2021-10-25
KR102861944B1 (ko) 2025-09-26
IL276814A (en) 2020-10-29
CL2020002177A1 (es) 2021-01-08
EA202092002A1 (ru) 2021-01-21
PE20211447A1 (es) 2021-08-05
EP3755696A1 (fr) 2020-12-30
US20220402921A1 (en) 2022-12-22
MX2020008852A (es) 2020-10-14
AU2019224075A1 (en) 2020-09-10
JP7369132B2 (ja) 2023-10-25
CN112020501A (zh) 2020-12-01
US11713320B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
MA51908A (fr) Indazole-3-carboxamides substitués par hétéroaryle en position 5, préparation et utilisation associées
EP3732185A4 (fr) Conjugués et préparation et utilisation associées
EP3479841A4 (fr) Dérivé du glucagon, conjugué de celui-ci, composition le comprenant et utilisation thérapeutique de celui-ci
SG11202011262YA (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
EP3450460A4 (fr) Conjugué de liaison multi-spécifique, compositions pharmaceutiques associées et utilisation
EP3838893A4 (fr) Lieur, conjugué anticorps-médicament le comprenant et utilisation associée
EP3505519A4 (fr) Composés hétérotricyclo à substitution par pyridinamine, leur préparation et leur utilisation dans des médicaments
IL283539A (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
IL283942A (en) Tubulysins and protein-tubulysin conjugates
SI3268374T1 (sl) KV1.3 inhibitorji in njihova medicinska uporaba
EP3434666A4 (fr) Dérivé d'arylamine et utilisation correspondante
EP3891205A4 (fr) Polyesters comprenant 2, 2, 4, 4-tétraalkyl-1, 3-cyclobutanediol
EP3801130A4 (fr) Innovation pour armoires compactes
SI3768241T1 (sl) Topični sestavek, ki obsega kalicpotriol in betametazon dipropionat
EP3864058A4 (fr) Composition photodurcissable
DK3943066T3 (da) Misbrugsforebyggende formuleringer med amfetamin
LT3886793T (lt) Odos apsauginė plėvelė, apimanti odos būklę gerinančias sudedamąsias dalis
MA46235A (fr) 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
EP3814241A4 (fr) Séparateur et plaque de séparation
IL285938A (en) Human serum albumin in formulations
IL282999A (en) 1,3,4-oxadiazolone compound and pharmaceutical
UY4713S (es) Configuración aplicada en cuchara lacre
DE112018005709A5 (de) Spannbolzen, Tischplatte und Spannsystem
EP3806651A4 (fr) Ingrédient alimentaire comprenant clostridium tyrobutyricum
LT3534898T (lt) Sinergistinės kompozicijos, apimančios (r)-dimiracetamą (1) ir (s)-dimiracetamą (2) neraceminiu santykiu